COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022

被引：562

作者：

Kislaya, Irina ^{[1
,2
]}

Machado, Ausenda ^{[1
,2
]}

Magalhaes, Sarah

Rodrigues, Ana Paula

Franco, Rafael

Leitek, Pedro Pinto ^{[3
,4
]}

Dias, Carlos Matias ^{[1
,2
]}

Nunes, Baltazar ^{[1
,2
]}

机构：

[1] Inst Nacl Sailde Doutor Ricardo Jorge, Dept Epidemiol, Lisbon, Portugal

[2] Univ NOVA Lisboa, Ctr Invest Saude Publ, Escola Nacl Saude Publ, Lisbon, Portugal

[3] Serv Partilhados Minist Saude, Lisbon, Portugal

[4] Direcao Servi Informacao & Analise, Direcao Geral Saude, Lisbon, Portugal

来源：

EUROSURVEILLANCE | 2022年 / 27卷 / 37期

关键词：

D O I：

10.2807/1560-7917.ES.2022.27.37.2200697

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We measured vaccine effectiveness (VE) against COVID-19-related severe outcomes in elderly people in Portugal between May and July 2022. In 2 80 year -olds, the second booster dose VE was 81% (95% CI: 75-85) and 82% (95% CI: 77-85), respectively, against COVID-19-related hospitalisation and death. The first booster dose VE was 63% (95% CI: 55-70) in 2 80 year -olds and 74% (95% CI: 66-80) in 60-79 year-olds against hospitalisation, and 63% (95% CI: 57-69) and 65% (95% CI: 54-74) against death.

引用

页数：6